- Residency - UT Southwestern Medical Center (1997-2000), Internal Medicine
- Fellowship - University of California at San Diego School of Medicine (2002-2005), Pulmonary Diseases & Critical Care Medicine
- Medical School - UT Southwestern Medical School (1992-1996)
Kelly Chin, M.D.
- Internal Medicine - Pulmonary and Critical Care Medicine
- Lung (Pulmonary) Disorders
- Pulmonary Hypertension
New Patient Appointment Accepting Virtual Visits or 214-645-6616
Biography
Kelly Chin, M.D., is a Professor of Internal Medicine and Director of Pulmonary Hypertension Clinical Research at UT Southwestern Medical Center, and also serves as the Director of the Heart Lung Clinic. She specializes in the treatment and research of pulmonary hypertension.
Dr. Chin attended UT Southwestern for her medical degree and her residency in internal medicine. She went to the University of California, San Diego, for a fellowship in pulmonary, critical care, and pulmonary hypertension. She joined the UT Southwestern faculty in 2005.
She conducts clinical research into pulmonary hypertension treatments, markers of prognosis, and risk factors for the development of pulmonary hypertension.
Dr. Chin is board certified in pulmonary disease and in critical care medicine by the American Board of Internal Medicine.
She has been recognized as a leader in her field, serving on multiple clinical trial steering committees and serving as an Associate Editor for Circulation. She has also received several teaching awards, and has been listed consistently on Texas Monthly's "Super Doctors" and D Magazine's "Best Doctors" lists.
Meet Dr. Chin
Pulmonary Hypertension Specialist
When pulmonologist Kelly Chin, M.D., started treating patients with pulmonary hypertension, it was a newly treatable disease – only six years before, there were no effective treatment options for most people with the disease.
"We offer access to the best treatments for pulmonary hypertension."
Since then, she's witnessed multiple advances in treatment options for patients who suffer from this often fatal disease. The opportunity for her patients to live a better life motivates her.
"After we've started them on therapy, we can see patients get better and really respond in a positive way,” she says. “It's very rewarding as a physician to impact someone's life in that way."
As Director of UT Southwestern Medical Center's Pulmonary Hypertension Clinical Research Program, Dr. Chin has also seen the Program grow quickly. It now ranks among the largest centers in the country, providing access to state-of-the-art treatments.
In addition to clinical care, Dr. Chin spends time researching causes and new treatments for pulmonary hypertension. While experts have identified some risk factors for the disease such as medication exposures and certain genes, there is a need to learn more. Dr. Chin is exploring other potential causes, such as a possible connection between stimulant use and pulmonary hypertension.
Dr. Chin loves seeing the impact new therapies can have on her patients. A pulmonary hypertension diagnosis no longer means a patient is going to die within a few years, she says.
"While it’s still a serious condition, many people improve and feel a lot better,” Dr. Chin notes. “It's certainly treatable. Patients can achieve a significant improvement in quality-of-life with medication."
Education & Training
Professional Associations & Affiliations
- Pulmonary Hypertension Association
- American Thoracic Society
- American Medical Association
- American College of Chest Physicians
Honors & Awards
- D Magazine Best Doctor 2021-2022
- College of Natural Science Dean’s Honor List 1989-1992 1990
- Southwestern Medical Foundation Medical School Scholarship 1992-1996 1992
- College of Natural Sciences College Scholar Award 1992
- Finalist, Alfred Soffer Research Award 2007, ACCP Original Research Award
Books & Publications
-
Books
-
Pulmonary Hypertension in Murray and Nadel's Textbook of Respiratory Medicine
Chin KM, Channick RN. (2015) -
Chronic Thromboembolic Pulmonary Hypertension in Pulmonary Vascular Disease
Chin K, Fedullo P. (2006) -
Surgical Treatments in Pulmonary Hypertension. A Patient's Survival Guide
Chin KM, Torres F (2011)
-
Pulmonary Hypertension in Murray and Nadel's Textbook of Respiratory Medicine
-
Publications
-
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
Author Collaboration TS, Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins Ca, Parsley E, Aranda R, Zisman LS, Ghofrani HA, Adir Y, Baillie T, Baratz D, Burger C, Chakinala MM, Cifrián Martínez JM, Delcroix M, Dwyer N, Elwing JM, Fisher M, Franco V, Grünig E, Highland K, Hill N, Hirani N, Hoeper M, Jansa P, Keogh A, Kingrey J, Lopez-Meseguer M, McConnell JW, Mehta S, Melendres-Groves L, Opitz C, Pepke-Zaba J, Pillutla P The Lancet Respiratory Medicine 2024 Jul 12 523-534 -
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset
Channick R, Chin KM, McLaughlin VV, Lammi MR, Zamanian RT, Turricchia S, Ong R, Mitchell L, Kim NH Cardiology and Therapy 2024 Jun 13 315-339 -
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studies
Lawrie A, Chin K, Fong YL, Gargano C, Gitton X, He C, Kiely DG, Zhou L, Zhou L, Maron BA, Quinn D, Rosenkranz S, Stamatiadis D, Toshner M, Wilkins MR, Howard L, Preston IR Pulmonary Circulation 2024 Apr 14 -
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies
Kim NH, Chin KM, McLaughlin VV, DuBrock H, Restrepo-Jaramillo R, Safdar Z, MacDonald G, Martin N, Rosenberg D, Solonets M, Channick R Pulmonary Therapy 2024 Mar 10 85-107 -
Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)
McLaughlin V, Farber HW, Highland KB, Hemnes AR, Chakinala MM, Chin KM, Han M, Cho M, Tobore T, Rahman M, Kim NH Journal of Heart and Lung Transplantation 2024 Feb 43 272-283 -
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities
McLaughlin VV, Sitbon O, Chin KM, Galiè N, Hoeper MM, Kiely DG, MacDonald G, Martin N, Mathai SC, Peacock A, Tawakol A, Torbicki A, Noordegraaf AV, Rosenkranz S European Journal of Heart Failure 2024 -
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension
Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM Journal of the American College of Cardiology 2024 Jan 83 473-484 -
Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
Abu-Rmaileh M, Mirza O, Patel C, Shah T, Hardin EA, Bartolome SD, Chin KM Pulmonary Circulation 2023 Apr 13 -
Disentangling the Pulmonary Capillary Wedge Pressure from the Pulmonary Artery Pressure as the Hemodynamic Underpinning of Bendopnea
Thibodeau JT, Ravipati G, Pham DD, Ayers CR, Hardin EA, Chin KM, Grodin JL, Drazner MH Circulation: Heart Failure 2023 Feb 16 E010169 -
Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?
Chin KM, Santiago-Munoz P Circulation 2023 Feb 147 562-564 -
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
Gerry Coghlan J, Gaine S, Channick R, Chin KM, du Roure C, Gibbs JS, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson VF, Galiè N ERJ Open Research 2023 Jan 9 -
Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension
Satish T, Chin K, Patel N Cardiology Research 2023 14 403-408 -
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)
McLaughlin VV, Channick R, Kim NH, Frantz RP, McConnell JW, Melendres-Groves L, Miller C, Ravichandran A, Rodriguez-Lopez J, Brand M, Leroy S, Wetherill G, Chin KM Pulmonary Circulation 2022 Oct 12 -
Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study
Shah T, Manthena P, Patel C, Chuah A, Hardin EA, Torres F, Bartolome SD, Chin KM CHEST 2022 Sep 162 669-683 -
Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?
Chin KM, Doelberg M, Martin N, Perchenet L, Galie N Journal of the American College of Cardiology 2022 Feb 79 e177 -
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM Advances in Therapy 2022 Jan 39 796-810 -
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, McLaughlin VV, Du Roure C, Rubin LJ, Sitbon O, Tapson V, Lang IM European Journal of Heart Failure 2022 Jan 24 205-214 -
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
Klose H, Chin KM, Ewert R, Gall H, Parambil J, Poch D, Seyfarth HJ, Axelsen LN, Hsu Schmitz SF, Stein C, Preston IR Respiratory Research 2021 Dec 22 -
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up
Kerr KM, Elliott CG, Chin K, Benza RL, Channick RN, Davis RD, He F, LaCroix A, Madani MM, McLaughlin VV, Park M, Robbins IM, Tapson VF, Terry JR, Test VJ, Jain S, Auger WR CHEST 2021 Nov 160 1822-1831 -
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JS, Grünig E, Hoeper MM, Martin N, Mathai SC, McLaughlin VV, Perchenet L, Poch D, Saggar R, Simonneau G, Galiè N Journal of the American College of Cardiology 2021 Oct 78 1393-1403 -
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study
Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galiè N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I CHEST 2021 Jul 160 277-286 -
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a prospective, longitudinal study
Kerr KM, Elliott CG, Benza RL, Channick RN, Chin KM, Davis RD, Jain S, LaCroix AZ, Madani MM, McLaughlin VV, Park MH, Tapson VF, Auger WR JMIR Research Protocols 2021 May 10 -
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE
Kim NH, Hemnes AR, Chakinala MM, Highland KB, Chin KM, McLaughlin V, Zhao C, Narayan V, Farber HW Journal of Heart and Lung Transplantation 2021 Apr 40 279-288 -
Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
Hinkamp CA, Shah T, Bartolome S, Torres F, Chin KM Journal of Thoracic Disease 2021 Mar 13 1466-1475 -
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, Sitbon O, Zamanian RT, Hemnes AR, Cravets M, Bruey JM, Roscigno R, Mottola D, Elman E, Zisman LS, Ghofrani HA Pulmonary Circulation 2021 11 -
Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
Frantz RP, Chin KM, Zhao C, Flynn M, Badesch D Pulmonary Circulation 2020 Apr 10 -
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM Journal of Heart and Lung Transplantation 2020 Apr 39 300-309 -
Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
Sodimu A, Bartolome S, Igenoza OP, Chin KM Pulmonary Circulation 2020 10 -
“Treat-to-close”: Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry
Bradley EA, Ammash N, Martinez SC, Chin K, Hebson C, Singh HS, Aboulhosn J, Grewal J, Billadello J, Chakinala MM, Daniels CJ, Zaidi AN International Journal of Cardiology 2019 Sep 291 127-133 -
Differentiating Precapillary from Postcapillary Pulmonary Hypertension: Pulmonary Artery Wedge Pressure Versus Left Ventricular End-Diastolic Pressure
Naeije R, Chin K Circulation 2019 Aug 140 712-714 -
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III GRIPHON Study
Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF Circulation 2019 May 139 2440-2450 -
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N European Journal of Heart Failure 2019 Mar 21 352-359 -
Discordance between imaging modalities in the evaluation of chronic thromboembolic pulmonary hypertension: A combined experience from two academic medical centers
Furfaro D, Azadi J, Housten T, Kolb TM, Damico RL, Hassoun PM, Chin K, Mathai SC Annals of the American Thoracic Society 2019 Feb 16 277-280 -
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study
Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V Journal of Heart and Lung Transplantation 2019 Jan 38 43-50 -
Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: An update
Noordegraaf AV, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R European Respiratory Journal 2019 Jan 53 -
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial
Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB CHEST 2018 Oct 154 848-861 -
Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids
Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM CHEST 2018 Sep 154 532-540 -
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ Journal of Heart and Lung Transplantation 2018 Mar 37 401-408 -
Update on pulmonary arterial hypertension research: proceedings from a meeting of experts
McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L Current Medical Research and Opinion 2018 Feb 34 263-273 -
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N Journal of the American College of Cardiology 2018 Feb 71 752-763 -
The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
Sato T, Ambale-Venkatesh B, Lima JA, Zimmerman SL, Tedford RJ, Fujii T, Hulme OL, Pullins EH, Corona-Villalobos CP, Zamanian RT, Minai OA, Girgis RE, Chin K, Khair R, Damico RL, Kolb TM, Mathai SC, Hassoun PM Pulmonary Circulation 2018 Feb 8 -
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S American Journal of Cardiovascular Drugs 2018 Feb 18 37-47 -
Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in scleroderma-associated pulmonary arterial hypertension
Mercurio V, Mukherjee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM American journal of respiratory and critical care medicine 2018 Feb 197 388-391 -
Lessons from the COMPASS-3 study
Shah T, Chin KM Pulmonary Circulation 2018 Jan 8 -
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM European Respiratory Journal 2017 Aug 50 -
Selexipag in the treatment of pulmonary arterial hypertension: Design, development, and therapy
Hardin EA, Chin KM Drug Design, Development and Therapy 2016 Nov 10 3747-3754 -
Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension
Darsaklis K, Dickson ME, Cornwell W, Ayers CR, Torres F, Chin KM, Matulevicius S International Journal of Cardiovascular Imaging 2016 Jul 32 1121-1130 -
Selexipag for the treatment of pulmonary arterial hypertension
Author Collaboration GI, Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV New England Journal of Medicine 2015 Dec 373 2522-2533 -
Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis
Pandey A, Garg S, Khunger M, Garg S, Kumbhani DJ, Chin KM, Berry JD Circulation: Heart Failure 2015 Nov 8 1032-1043 -
Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension
Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC American journal of respiratory and critical care medicine 2015 Nov 192 1102-1110 -
Exercise echocardiography in connective tissue disease
Chin K, Mathai SC Journal of the American College of Cardiology 2015 Jul 66 385-387 -
Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: Results from a single center
Chin KM, Ruggiero R, Bartolome S, Velez-Martinez M, Darsaklis K, Kingman M, Harden S, Torres F Pulmonary Circulation 2015 5 513-520 -
Pulmonary Hypertension
Chin K, Channick RN 2015 Jan 2 1031-1049.e4 -
Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials
Chin KM, Bartolome S, Miller K, Blair C, Gillies H, Torres F International Journal of Clinical Practice 2014 May 68 568-577 -
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V American heart journal 2014 Feb 167 218-225.e1 -
Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology
Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM Journal of the American College of Cardiology 2013 Dec 62 D22-D33 -
Association of cardiac troponin i with disease severity and outcomes in patients with pulmonary hypertension
Vélez-Martínez M, Ayers C, Mishkin JD, Bartolome SD, Garcia CK, Torres F, Drazner MH, de Lemos JA, Turer AT, Chin KM American Journal of Cardiology 2013 Jun 111 1812-1817 -
Safety recommendations for administering intravenous prostacyclins in the Hospital
Kingman MS, Chin K Critical care nurse 2013 33 32-39 -
Left atrial structure and function and clinical outcomes in the general population
Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, Levine BD, Chin KM, de Lemos JA, Peshock RM, Drazner MH European heart journal 2013 Jan 34 278-285 -
Characterizing the right ventricle: Advancing our knowledge
Chin KM, Coghlan G American Journal of Cardiology 2012 Sep 110 S3-S8 -
International classification of diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: Implications for database studies
Link J, Glazer C, Torres F, Chin K CHEST 2011 Mar 139 497-504 -
Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension
Blalock SE, Matulevicius SA, Mitchell LC, Reimold SC, Warner JJ, Peshock RM, Torres F, Chin KM Journal of Cardiac Failure 2010 Feb 16 121-127 -
Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: A national survey
Kingman MS, Tankersley MA, Lombardi S, Spence S, Torres F, Chin KS Journal of Heart and Lung Transplantation 2010 29 841-846 -
Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension
Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ CHEST 2009 Jan 135 130-136 -
Telomere shortening in familial and sporadic pulmonary fibrosis
Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK American journal of respiratory and critical care medicine 2008 Oct 178 729-737 -
Reply
Chin KM, Rubin LJ Journal of the American College of Cardiology 2008 Aug 52 792 -
Changes in Right Ventricular Structure and Function Assessed Using Cardiac Magnetic Resonance Imaging in Bosentan-Treated Patients With Pulmonary Arterial Hypertension
Chin KM, Kingman M, de Lemos JA, Warner JJ, Reimold SC, Peshock RM, Torres F American Journal of Cardiology 2008 Jun 101 1669-1672 -
Pulmonary Arterial Hypertension
Chin KM, Rubin LJ Journal of the American College of Cardiology 2008 Apr 51 1527-1538 -
Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: Correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels
Chin KM, Channick RN, Kim NH, Rubin LJ CHEST 2007 Sep 132 786-792 -
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - Seven sites, United States, 2003-2006
Barst R, Berman-Rosenzweig E, Horn E, Saiman L, Lee L, Southwick K, Kohlerschmidt D, Smith P, Gomberg-Maitland M, Weber S, Ivy D, Doran A, McGoon M, Anderson Severson C, Rubenfire M, McLaughlin V, Feldman J, Tanner C, Chin K, Kingman M, Tapson V, Srinivasan A, Noble-Wang J, Arduino M, Shoulson R, Petersen E, Kallen A, Lederman E, Balaji A, Trevino I Morbidity and Mortality Weekly Report 2007 Mar 56 170-172 -
Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
Chin KM, Channick RN, Rubin LJ CHEST 2006 Dec 130 1657-1663 -
Chronic Thromboembolic Pulmonary Hypertension
Chin KM, Fedullo PF 2006 Jan 188-209 -
The right ventricle in pulmonary hypertension
Chin KM, Kim NH, Rubin LJ Coronary artery disease 2005 Feb 16 13-18 -
Bosentan
Chin K, Channick R Expert Review of Cardiovascular Therapy 2004 Mar 2 175-182
-
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
Research
- Pulmonary Hypertension
Clinical Focus
- Lung (Pulmonary) Disorders
- Pulmonary Hypertension
Q&A by Dr. Chin
Results: 1 Locations
University Hospital Heart and Lung Clinic
at Professional Office Building 2 5939 Harry Hines Blvd., 6th Floor, Suite 600Dallas, Texas 75390 214-645-5505 Directions to University Hospital Heart and Lung Clinic Parking Info for University Hospital Heart and Lung Clinic
New Patient Appointment Accepting Virtual Visits or 214-645-6616